238 related articles for article (PubMed ID: 38338909)
21. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
22. Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers.
Li B; Feng Y; Hou Q; Fu Y; Luo Y
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806187
[TBL] [Abstract][Full Text] [Related]
23. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
24. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
25. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
Daley BR; Vieira HM; Rao C; Hughes JM; Beckley ZM; Huisman DH; Chatterjee D; Sealover NE; Cox K; Askew JW; Svoboda RA; Fisher KW; Lewis RE; Kortum RL
Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2313137120. PubMed ID: 37972068
[TBL] [Abstract][Full Text] [Related]
26. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
27. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
28. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
29. ALDH6A1 weakens the progression of colon cancer via modulating the RAS/RAF/MEK/ERK pathway in cancer cell lines.
Li X; Wang N; Wu Y; Liu Y; Wang R
Gene; 2022 Oct; 842():146757. PubMed ID: 35907565
[TBL] [Abstract][Full Text] [Related]
30. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
31. RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas.
Hanrahan AJ; Solit DB
Cancer Discov; 2012 Aug; 2(8):666-9. PubMed ID: 22886659
[TBL] [Abstract][Full Text] [Related]
32. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
[TBL] [Abstract][Full Text] [Related]
33. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
Diehl JN; Klomp JE; Snare KR; Hibshman PS; Blake DR; Kaiser ZD; Gilbert TSK; Baldelli E; Pierobon M; Papke B; Yang R; Hodge RG; Rashid NU; Petricoin EF; Herring LE; Graves LM; Cox AD; Der CJ
J Biol Chem; 2021 Nov; 297(5):101335. PubMed ID: 34688654
[TBL] [Abstract][Full Text] [Related]
34. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
35. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic dependency plays a dominant role in the immune response to cancer.
Li J; D'Amico S; Kirillov V; Petrenko O; Reich NC
Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2308635120. PubMed ID: 37782788
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
38. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
Hayes TK; Neel NF; Hu C; Gautam P; Chenard M; Long B; Aziz M; Kassner M; Bryant KL; Pierobon M; Marayati R; Kher S; George SD; Xu M; Wang-Gillam A; Samatar AA; Maitra A; Wennerberg K; Petricoin EF; Yin HH; Nelkin B; Cox AD; Yeh JJ; Der CJ
Cancer Cell; 2016 Jan; 29(1):75-89. PubMed ID: 26725216
[TBL] [Abstract][Full Text] [Related]
39. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
40. RAF-MEK-ERK pathway in cancer evolution and treatment.
Ullah R; Yin Q; Snell AH; Wan L
Semin Cancer Biol; 2022 Oct; 85():123-154. PubMed ID: 33992782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
